Arcellx (ACLX) Insider Trading Activity 2025 - MarketBeat

6 days ago · How much insider selling is happening at Arcellx? Insiders have sold a total of 2,900,417 Arcellx shares in the last 24 months for a total of $150,603,205.68 sold. Arcellx Key …

$150603205.68
OFF

Arcellx (ACLX) Insider Trading Activity 2025 - MarketBeat

2 weeks from now

6 days ago · How much insider selling is happening at Arcellx? Insiders have sold a total of 2,900,417 Arcellx shares in the last 24 months for a total of $150,603,205.68 sold. Arcellx Key …

marketbeat.com

$79.02
OFF

Insider Selling: Arcellx, Inc. (NASDAQ:ACLX) Director Sells 1,500 ...

2 weeks from now

Dec 27, 2024 · Arcellx Trading Up 1.9 %. Shares of NASDAQ:ACLX opened at $79.02 on Friday. Arcellx, Inc. has a 12 month low of $47.88 and a 12 month high of $107.37. The company has …

insidertrades.com

$98805.00
OFF

Arcellx, Inc. (NASDAQ:ACLX) Director Sells $98,805.00 In Stock

2 weeks from now

1 day ago · Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) Director Kavita Patel sold 1,500 shares of the firm's stock in a transaction on Tuesday, January 14th. The stock was sold at an …

insidertrades.com

$2263942
OFF

Arcellx Insider Sold Shares Worth $2,263,942

2 weeks from now

2 days ago · Redburn Initiates Arcellx at Buy With $109 Price Target 24-10-08: MT Arcellx Insider Sold Shares Worth $1,840,053, According to a Recent SEC Filing ... (ACLX) ARCELLX …

marketscreener.com

$261820.57
OFF

Arcellx, Inc. (NASDAQ:ACLX) Insider Sells $261,820.57 In Stock

2 weeks from now

4 days ago · Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) insider Christopher Heery sold 3,553 shares of the firm's stock in a transaction dated Wednesday, January 8th. The shares …

marketbeat.com

7%
OFF

Arcellx CEO Elghandour Sells Stock Worth $2.26 Million

2 weeks from now

6 days ago · The transaction comes as the stock has experienced a 12.7% decline over the past week, though InvestingPro data shows analysts maintain a strong buy consensus with price …

investing.com

$711835.30
OFF

Arcellx, Inc. (NASDAQ:ACLX) Insider Sells $711,835.30 In Stock

2 weeks from now

Jul 19, 2024 · Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) insider Christopher Heery sold 10,901 shares of the business's stock in a transaction dated Tuesday, July 16th. The shares …

insidertrades.com

$121.00
OFF

Promising Potential Of Arcellx Inc.: Buy Rating ... - Markets Insider

2 weeks from now

2 days ago · Analyst John Newman from Canaccord Genuity maintained a Buy rating on Arcellx Inc (ACLX – Research Report) and keeping the price target at $121.00. Discover …

businessinsider.com

49%
OFF

(ACLX) - Analyzing Arcellx's Short Interest

2 weeks from now

1 day ago · Arcellx's ACLX short percent of float has risen 6.49% since its last report. The company recently reported that it has 5.81 million shares sold short , which is 12.3% of all …

benzinga.com

$4.79
OFF

Arcellx, Inc. (NASDAQ:ACLX) Shares Sold By JPMorgan Chase & Co.

2 weeks from now

6 days ago · Insider Buying and Selling at Arcellx. ... Shares of ACLX traded down $4.79 during mid-day trading on Thursday, hitting $72.26. 884,285 shares of the company were exchanged, …

marketbeat.com

$236217.37
OFF

Arcellx, Inc. (NASDAQ:ACLX) Insider Sells $236,217.37 In Stock

2 weeks from now

Jan 7, 2025 · Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) insider Christopher Heery sold 3,061 shares of the business's stock in a transaction that occurred on Monday, January 6th. …

insidertrades.com

40%
OFF

Insider Trading For ACLX: Analyze Insider Buying And Selling For ...

2 weeks from now

Gain valuable insights into insider buying and selling activities related to ACLX stock. ... Arcellx, Inc. Follow stock. Buy ACLX. $69.08. Last price-4.40% Day's change. $3.74B. Market cap. …

insideralerts.co

$54466094.78
OFF

ACLX Insider Trading | Arcellx Buys And Sells

2 weeks from now

Insider Selling (Last 12 Months): $54,466,094.78 Arcellx Insider Trading History Chart This chart shows the insider buying and selling history at Arcellx by year and by quarter.

insidertrades.com

FAQs about Arcellx (ACLX) Insider Trading Activity 2025 - MarketBeat Coupon?

Should investors buy arcellx (aclx) stock?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACLX shares. View ACLX analyst ratings or view top-rated stocks. ...

Where can I buy aclx stock?

Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. ...

What are analysts' expectations for aclx shares?

Their ACLX share price forecasts range from $32.00 to $104.00. On average, they predict the company's stock price to reach $43.36 in the next year. This suggests a possible upside of 40.7% from the stock's current price. View analysts price targets for ACLX or view top-rated stocks among Wall Street analysts. How have ACLX shares performed in 2023? ...

Is arcellx (arcellx) a good stock to buy?

Arcellx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings. According to analysts' consensus price target of $43.36, Arcellx has a forecasted upside of 40.7% from its current price of $30.81. ...

How many research reports have been made about arcellx?

Arcellx has only been the subject of 4 research reports in the past 90 days. Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. ...

Why did John Newman buy arcellx Inc?

John Newman has given his Buy rating due to a combination of factors that highlight the promising potential of Arcellx Inc. The company is poised to release significant data from its iMMagine-1 trial in mid-2025, which is expected to demonstrate strong efficacy in treating later-line multiple myeloma. ...